MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it ...

YAVNE, Israel - MediWound Ltd. (NASDAQ:MDWD), a biopharmaceutical company specializing in enzymatic therapies for tissue repair, has launched a Phase III clinical trial for its product EscharEx®, ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...

YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics ...

MediWound (MDWD) shares ended the last trading session 8.5% higher at $19.83. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Mediwound ( (MDWD)) has shared an announcement. Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment ...

Shares of MediWound stock opened at $16.72 on Friday. The business has a 50-day simple moving average of $17.24 and a 200 day simple moving average of $17.66. MediWound has a one year low of $11. ...

Zacks Can MediWound Climb 57.49% to Reach the Level Wall Street Analysts Expect? MediWound (NASDAQ: MDWD) closed the last trading session at $18.89, gaining 21.4% over the past four weeks ...

Short MDWD slightly under 21.14, target 18.58, stop loss @ 21.2 Check the time stamp on this data. Updated AI-Generated Signals for Mediwound Ltd. (MDWD) available here: MDWD. Type a few symbols and ...

Given the large stake in the stock by institutions, MediWound's stock price might be vulnerable to their trading decisions 50% of the business is held by the top 8 shareholders Ownership research ...

YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive ...